Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline - Wikidata - awgldk - TriplyDB

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

http://www.wikidata.org/entity/Q34448553

about

Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET A Review of Imaging Methods for Prostate Cancer Detection.Contemporary approaches for imaging skeletal metastasis Clinical molecular imaging with radiotracers: current status The use of (18)F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer.Imaging metabolic heterogeneity in cancer Imaging on nodal staging of prostate cancer.Radiation treatment monitoring using multimodal functional imaging: PET/CT ((18)F-Fluoromisonidazole & (18)F-Fluorocholine) and DCE-US.Radiolabelled probes for imaging of atherosclerotic plaques.Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.Vitamin D, intermediary metabolism and prostate cancer tumor progression.Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence.Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature.Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer Prognostic Utility of PET in Prostate Cancer.Transbilayer phospholipids molecular imaging.(11)C-acetate PET/CT in pre-therapeutic lymph node staging in high-risk prostate cancer patients and its influence on disease management - a retrospective study.Can Choline PET Tackle the Challenge of Imaging Prostate Cancer?Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy.Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer The metabolic fate of acetate in cancer.Functional imaging for prostate cancer: therapeutic implications.Molecular imaging of prostate cancer: PET radiotracers.Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.[18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations.Promise and pitfalls of quantitative imaging in oncology clinical trials.PET/CT in prostate cancer: non-choline radiopharmaceuticals.Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake (18)F Sodium Fluoride PET/CT in Patients with Prostate Cancer: Quantification of Normal Tissues, Benign Degenerative Lesions, and Malignant Lesions New and emerging therapies for bone metastases in genitourinary cancers.Detection of prostate cancer by an FDG-PET cancer screening program: results from a Japanese nationwide survey.Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction.The Medical Case for a Positron Emission Tomography and X-ray Computed Tomography Combined Service in Oman.PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.Quantitative 18F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring.Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

P2860

Q24633858-E732A3F6-AE26-4E2E-ADE3-A44D23D130DF Q26766398-A0D64746-ECCC-4FB0-8CFC-87292067E832 Q26798170-BF26D09C-C37F-40CD-9441-3BAE1A2F2BA5 Q26994741-3D7FD2EF-093F-4868-8969-C5A0BF64995E Q27300759-F581B61D-A835-419F-8011-A72610F8C2EA Q28076500-9AC45BC5-F094-4880-8971-CBD6A6EE2960 Q30244033-35677F19-8889-4FFD-9252-A5E6079B14A2 Q30395717-328FC420-7C3D-41F1-AFC0-13F8E8E816A8 Q30577193-B9958281-BE2F-4596-AE5B-36E784260690 Q33625371-F5D423F6-BB7A-45C4-8854-185F307B3BAF Q33647013-11EA447C-5D1C-4D56-972B-1DD1F46113D5 Q33789117-C6719CC8-75C8-46F4-9874-266B32DECD49 Q33804178-8F4A4774-E49C-470A-9591-4054B0822312 Q34062324-9DD8E66F-AED6-4801-AB7A-548D3F404EE8 Q34123665-A28F6E9F-B447-48B1-8C36-C50694B5DFF0 Q34465066-B4E31322-C06B-4FCD-B5D8-E375E35F2A64 Q35244433-F680B876-1B1D-44EE-8A1E-B6FBD5D09EBE Q35650805-F85CAA3E-3C7E-43C4-BFAA-F6D4CB3316B0 Q35675382-4D46AFF0-D854-4375-86EB-D6061F7B7734 Q35849169-A4DF4903-5197-45CD-97E8-E03A6748C03B Q36023165-544FCA4E-93FB-47B9-846F-18D49CAC3BA9 Q36039090-372B7BBD-050A-42D7-B234-04D5005E15EE Q36113718-03D778BC-4054-4F43-AD87-FE4CCB62F187 Q36128629-EFCDA377-B6D0-41ED-8126-D1A7B6330208 Q36129937-BA0DD4D0-3907-43DA-9069-6CE00D6A56A9 Q36181578-CB41582A-A434-47DB-81B9-69C3946F07AB Q36236041-1F71A4DD-6D93-4F47-A39F-0114E3DC08AE Q36303765-593314EC-F176-436A-A685-94C722A4B059 Q36308766-1483648F-BD2A-46D2-936E-6D028FB531C7 Q36533826-DB22549D-D56F-430F-BD0A-4D5D49CC1AC0 Q36733087-815E2241-BEC6-4518-B34B-4F57F28E69BD Q36866291-C90707AC-0CEF-49DC-8B9A-3537337EFC8E Q37077347-EECE7632-B7EE-45E5-B86C-6DE570737E41 Q37086178-ABBDB3CA-284A-4056-B757-0018418EFA38 Q37209479-8D342B6A-E0A0-4F2A-9131-A4D61FDB86DA Q37332675-C5B55752-9BDC-4133-B5F9-A1BD4244B45D Q37390670-4D97035E-0C72-464F-AAD8-31DF6CDB51D8 Q37714485-4B488852-54FE-43BD-8145-A9F0A3137836 Q37721529-DE95B183-1C01-4DBE-95C1-76FD87955BC6 Q37918311-7AEE8E32-8E84-465B-8AA3-BB9ED6B440DB

P2860

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

http://www.wikidata.org/entity/Q34448553

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

@ast

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

@en

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

@nl

type

label

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

@ast

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

@en

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

@nl

prefLabel

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

@ast

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

@en

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

@nl

P1433

Q34448553-988C54F7-6EE8-468D-BE37-38129ACEDD61

P1476

Q34448553-EACED379-AB59-44D5-B73A-0198218C3742

P2093

Q34448553-685226B3-335E-403A-91ED-42786ABB9590

P2860

Q34448553-0B30D473-25B8-4B91-B585-657F9C3B06A4

Q34448553-0BB3BAED-F3D5-4C78-9C70-77ADF9CC9E65

Q34448553-0D0511CE-BED4-498A-8A81-0A210124E727

Q34448553-0DCC2894-F966-4568-BEFE-5526C20AA6B3

Q34448553-0E6A7926-0598-4D93-B83C-742D980EB0FF

Q34448553-1820FD09-6136-4130-8BEA-DB0DD8F7DE0E

Q34448553-19D7D533-5D10-4D28-BFEF-1D9C88051311

Q34448553-2A7C4CC7-7182-457B-9244-8FDB2A67BDBF

Q34448553-2B9586CD-CC37-4E99-A6CA-B821D5F124C4

Q34448553-2C0136CC-BBB5-4F78-8DD8-5415899C0DEE

P304

Q34448553-4BA33591-9A2C-45F0-95C8-6732A83056F8

P31

Q34448553-84277778-DC8C-49BC-B50A-9DE3CBF884D6

Q34448553-d8932e82-3035-459b-b368-c6a13eef4681

P356

Q34448553-623CC9F8-E57B-409F-AB49-482EA567E4E1

P407

Q34448553-B79B3386-FA7A-473B-9D7F-C3818EDACA82

P433

Q34448553-10691EC1-A1E9-4E0F-86C6-BD6AD7EF84EA

P478

Q34448553-7D61A7E5-AA26-47F9-B0B0-B3FC24BD8883

P577

Q34448553-DD8BDA90-D5CC-4FD6-B24C-CFD02F89F4FC

P5875

Q34448553-99612089-E53E-4FC6-AF12-56478AB27832

P698

Q34448553-5AB6571B-6A5B-4998-A0D5-B6897B3136BD

P932

Q34448553-B7C36B76-F542-46A7-85F3-8B26C0B0D7C0

P356

JNUMED.110.077941

P1433

The Journal of Nuclear Medicine

P1476

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

@en

P2093

Hossein Jadvar

http://www.w3.org/2001/XMLSchema#string

P2860

Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer.

Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.

Natural history of progression after PSA elevation following radical prostatectomy.

The role of the androgen receptor in the development and progression of prostate cancer.

Mammalian hexokinases and their abnormal expression in cancer.

Prostate cancer staging using imaging.

Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer.

Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.

[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.

The natural history of prostate cancer.

P304

81-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.110.077941

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49675301

http://www.w3.org/2001/XMLSchema#string

P698

21149473

http://www.w3.org/2001/XMLSchema#string

P932

3012154

http://www.w3.org/2001/XMLSchema#string